Quanterix Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Quanterix hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.4%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.95
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

Jun 27

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Apr 14

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von QTRX in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von QTRX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Quanterix Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von QTRX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (QTRX)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Life Sciences)	0.4%
Analystenprognose in 3 Jahren (QTRX)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von QTRX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von QTRX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von QTRX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da QTRX keine Ausschüttungen gemeldet hat.

Quanterix Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024

Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 9.7% to US$29.80

New minor risk - Shareholder dilution

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 11% to US$33.25

New minor risk - Shareholder dilution

Quanterix Corporation Revises Earnings Guidance for the 2023

Quanterix Corporation Revises Earnings Guidance for the 2023

New major risk - Revenue and earnings growth

Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023

Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Price target increased by 9.7% to US$31.00

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Consensus estimates of losses per share improve by 20%

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023

Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$15.25

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Brian Blaser to Board of Directors

Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022

Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022

Quanterix Corporation: Selling For Less Than Cash Value

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer

Quanterix stock gains after insider buys reported by CEO and CFO

Consensus forecasts updated

Independent Director recently bought US$2.0m worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$34.50

Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

President recently sold US$85k worth of stock

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022

Consensus forecasts updated

Price target decreased to US$45.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q1, 2022 Results on May 10, 2022

Quanterix Corporation, Annual General Meeting, Jun 23, 2022

Quanterix Corporation Grants Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

Quanterix Corporation announced that it has received funding from Alzheimers Drug Discovery Foundation

We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely

Consensus forecasts updated

Quanterix Announces Executive Leadership Succession Plan, Effective April 25, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation to Report Q4, 2021 Results on Mar 01, 2022

Is Quanterix (NASDAQ:QTRX) A Risky Investment?

Insider recently sold US$98k worth of stock